These findings suggest that NAD+/Sirt2-dependent GKRP deacetylation regulation plays an important role in HGU control and that this regulation is a novel therapeutic target in type 2 diabetes and obesity and is responsible for HGU impairment. The gene discussed is SIRT2; the disease is type 2 diabetes mellitus.